Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CD30+ classical Hodgkin lymphoma~* Supradiaphragmatic Ann Arbor clinical stage I or II~* Previously untreated~* PET scan without IV contrast at diagnosis available for central review with at least one hypermetabolic lesion~* Unfavourable (U) characteristics according to the classic EORTC/LYSA clinical prognostic factors, including patients with at least one of the following factors:~  * CSII ≥ 4 nodal areas~ * age ≥ 50 yrs~ * M/T ratio ≥ 0.35~ * ESR ≥ 50 (without B-symptoms) or ESR ≥ 30 with B-symptoms~* ECOG performance status 0-2~* Life expectancy \> 6 months~* Age 18 to 60 years~* Availability for periodic blood sampling, study-related assessments, and management of toxicity at the treating institution.~* Female patients who:~  * Are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR~ * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, through 6 months after the last dose of study drug, OR agree to completely abstain from heterosexual intercourse~* Male patients, even if surgically sterilized (ie, status postvasectomy), who:~  o Agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.~* Written informed consent.~* Required baseline laboratory data:~  * Absolute neutrophil count ≥ 1,500/µL~ * Platelet count ≥ 75,000/ µL~ * Hemoglobin ≥ 8g/dL~ * Serum total bilirubin ≤ 1.5 X ULN unless the elevation is known to be due to Gilbert syndrome.~ * Serum creatinine ≤ 2.0 mg/dL and/or calculated creatinine clearance \> 40 mL/minute (Cockcroft-Gault formula or MDRD)~ * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN~Exclusion Criteria:~* Histological diagnosis different from classical Hodgkin Lymphoma. Nodular lymphocyte predominant subtypes (nodular paragranuloma or Poppema paragranuloma) are excluded.~* Known cerebral or meningeal disease of any etiology, including signs or symptoms of PML~* Any sensory or motor peripheral neuropathy ≥ Grade 2~* Known history of any of the following cardiovascular conditions~  * Myocardial infarction within 2 years of randomization~ * New York Heart Association (NYHA) Class III or IV heart failure (see Appendix 14)~ * Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~ * Recent evidence (within 30 days before first dose of study drug) of a left-ventricular ejection fraction \<50%~* Unstable diabetes mellitus (to avoid uninterpretable FDG-PET scan).~* Known HIV positive~* HCV positive~* HBV positive. This means:~  * HBsAg positive~ * HBsAg negative, anti-HBs positive and/or anti-HBc positive and detectable viral DNA (HBsAg negative patients and viral DNA negative and patients seropositive due to a history of hepatitis B vaccine are eligible).~* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors. Carcinoma in situ of any type not excluded if complete resection.~* Dementia or altered mental status~* Pregnancy or breastfeeding.~* Previous treatment with any anti-CD30 antibody.~* Known hypersensitivity to any excipients contained in the BV formulation or known contra-indication to any drug contained in the chemotherapy regimens~* Treatment with corticosteroids before baseline PET scan~* Known active viral, bacterial, or fungal infection requiring treatment with antimicrobial therapy or with untreated known active Grade 3 viral, bacterial, or fungal infection, within 2 weeks prior to the first dose of BV~* Treatment with any investigational drug within 30 days before first cycle of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ABVD (Type: ACTIVE_COMPARATOR): Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
- AVD+BV (Type: EXPERIMENTAL): Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).